浙江海森药业股份有限公司 章 程 二〇二五年十月 1 | | | 浙江海森药业股份有限公司章程 浙江海森药业股份有限公司章程 第一章 总则 第一条 为规范浙江海森药业股份有限公司（以下简称"公司"或"本公司"） 的组织和行为，保护公司、股东、职工、债权人的合法权益，根据《中华人民共 和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下 简称"《证券法》"）和其他有关规定，结合公司的实际情况，制订本章程。 第二条 公司系依照《公司法》和其他有关规定成立的股份有限公司。 公司以发起设立方式由原有限责任公司浙江海森药业有限公司整体变更为 股份有限公司。公司在浙江省市场监督管理局注册登记，取得营业执照，统一社 会信用代码为 913307837045812886。 第三条 公司于 2023 年 3 月 16 日经中国证券监督管理委员会（以下简称"中 国证监会"）同意，首次向社会公众发行人民币普通股 1700 万股，于 2023 年 4 月 10 日在深圳证券交易所主板上市。股票简称：海森药业，股票代码：001367。 第四条 公司注册名称：浙江海森药业股份有限公司。 英文名称：ZHEJIANG HAI ...

证券代码：001367 证券简称：海森药业 公告编号：2025-054 浙江海森药业股份有限公司 关于 2024 年限制性股票激励计划首次授予部分 第一个解除限售期解除限售股份上市流通的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 1、2024年限制性股票激励计划首次授予部分第一个解除限售期解除限售条 件已经成就，符合解除限售条件的激励对象为85人，可解除限售的限制性股票数 量为119.1696万股，占公司目前总股本的0.7844%。 同日，公司召开第三届监事会第七次会议，审议通过了《关于<浙江海森药 业股份有限公司2024年限制性股票激励计划（草案）>及其摘要的议案》《关于 <浙江海森药业股份有限公司2024年限制性股票激励计划实施考核管理办法>的 议案》《关于核实<浙江海森药业股份有限公司2024年限制性股票激励计划首次 授予激励对象名单>的议案》。 （二）2024年9月13日至2024年9月22日，公司对本次激励计划拟首次授予激 励对象的姓名及职务进行了公示。截至公示期满，公司监事会未收到任何员工对 本次激励计划首次授予激励 ...

Core Insights - The raw material pharmaceutical industry is experiencing increased concentration, with China becoming the largest producer globally due to cost advantages and capacity expansion [1][2] - Haisen Pharmaceutical (001367.SZ) reported a revenue of 359 million yuan for the first three quarters of 2025, a year-on-year increase of 12.13%, and a net profit attributable to shareholders of 88 million yuan, up 1.45% [1] - The company's total assets reached 1.569 billion yuan, reflecting a growth of 5.55% year-on-year [1] Company Overview - Haisen Pharmaceutical specializes in the research, production, and sales of chemical pharmaceutical raw materials and intermediates, having developed a diverse product system focused on gastrointestinal, analgesic, and cardiovascular raw materials, supplemented by antibacterial and antidepressant products [1] - The company has cultivated high market shares in products such as sucralfate, phenacetin, atorvastatin calcium, and PHBA, while expanding sales and market share for products like escitalopram oxalate and parecoxib sodium in recent years [1] Market Strategy - The company is strengthening its domestic market presence through regional procurement participation to enhance market penetration [2] - Currently, Haisen has 17 ongoing research projects covering raw materials, intermediates, and formulations across various therapeutic areas, showcasing a diversified and cutting-edge R&D direction [2] - The overseas sales revenue increased by 53.04% year-on-year in the first half of the year, indicating improved competitiveness in the global market [2] Cost Management and Future Goals - Haisen Pharmaceutical is enhancing its risk resistance by optimizing procurement strategies, strategic partnerships, and centralized purchasing to lower raw material costs [2] - For the 2025 performance targets, the company aims to ensure supply, actively expand domestic and international markets, and leverage a cohesive core team through equity incentives to achieve annual performance goals [2]

Core Viewpoint - Zhejiang Haishen Pharmaceutical Co., Ltd. has completed the registration of the reserved grant for the 2024 restricted stock incentive plan, which includes the approval processes and details regarding the stock grants [1][2][3]. Summary by Sections Approval Procedures - The company held a board meeting on September 12, 2024, to approve the incentive plan and related documents, with reports from legal and independent financial advisors [1]. - The supervisory board also approved the plan and the list of initial grant recipients on September 12, 2024 [2]. - A temporary shareholders' meeting on September 30, 2024, further approved the incentive plan and related matters [3]. Reserved Grant Registration Details - The reserved grant date is set for September 11, 2025, with the listing date for the restricted stock on October 30, 2025 [4]. - A total of 424,760 shares will be granted, accounting for 0.2796% of the company's total equity at the time of the reserved grant [4]. - The grant price is set at 8.43 CNY per share, with 31 individuals receiving the grants [4][8][9]. Conditions and Restrictions - The incentive plan has a maximum validity period of 60 months from the completion of the initial grant registration [12]. - Different lock-up periods apply, with a minimum of 12 to 24 months for the reserved grants [13]. - The conditions for lifting the lock-up include the company's financial performance and the individual performance of the recipients [16][18]. Financial Impact - The total share capital will increase from 151,926,440 shares to 152,351,200 shares following the grant registration [21]. - The diluted earnings per share for 2024 is projected to be 0.80 CNY [22]. - Funds raised from the stock grants will be used to supplement working capital [23]. Compliance and Reporting - The company has confirmed that the stock grant does not affect its compliance with listing conditions and that the controlling shareholders' stakes remain unchanged [21]. - A verification report from the accounting firm confirms the funds received from the grant recipients [20].

证券代码：001367 证券简称：海森药业 公告编号：2025-053 浙江海森药业股份有限公司 关于 2024 年限制性股票激励计划预留授予登记完成的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 限制性股票预留授予日：2025年9月11日 预留授予的限制性股票上市日：2025年10月30日 预留授予的限制性股票登记数量：42.4760万股，占本激励计划预留授予 日公司股本总额的0.2796%。 限制性股票来源：公司向激励对象定向发行的本公司A股普通股股票 根据中国证券监督管理委员会《上市公司股权激励管理办法》、深圳证券交 易所、中国证券登记结算有限责任公司深圳分公司的有关规定，浙江海森药业股 份有限公司（以下简称"公司"）完成了2024年限制性股票激励计划（以下简称 "本次激励计划"或"本激励计划"）预留授予登记工作，现将有关事项说明如 下： 一、本次激励计划已履行的相关审批程序 （一）2024年9月12日，公司召开第三届董事会第七次会议，审议通过了《关 于<浙江海森药业股份有限公司2024年限制性股票激励计划（草案）>及其摘要 的议 ...

Core Insights - The company, Haisen Pharmaceutical (001367.SZ), reported a strong performance in its Q3 2025 financial results, achieving a revenue of 117 million yuan, representing a year-on-year growth of 6.74% [1] Group 1: Company Performance - Haisen Pharmaceutical maintains a stable operational performance despite a complex external environment [1] - The company has a diverse product portfolio, including active pharmaceutical ingredients (APIs) and solid formulations, with leading products such as Paroxetine Hydrochloride and Amikacin side-chain PHBA [1] - The market share for Sucralfate is approximately 60%, ranking first internationally, while the domestic market share for Amikacin side-chain PHBA and Methylsulfonylmethane is also over 60% [1] Group 2: Market and Expansion - The company has sufficient market orders for its main products, indicating a robust supply and demand situation [1] - Haisen Pharmaceutical is actively advancing the construction of a new green and intelligent pharmaceutical production base to enhance production capacity [1] - The company is expanding its market presence through a global layout, optimizing its market structure [1] Group 3: Strategic Partnerships - The company has established long-term cooperative relationships with several strategic partners, some lasting over 20 years, which has built a solid foundation for collaboration [2] - Haisen Pharmaceutical has formed stable partnerships with leading global clients, including TEVA, across multiple products [2]

Core Viewpoint - Haosen Pharmaceutical reported a revenue of 359 million yuan for the first three quarters of 2025, marking a year-on-year growth of 12.13%, and a net profit attributable to shareholders of 88 million yuan, with a growth of 1.45% [1] Financial Performance - The total assets of Haosen Pharmaceutical reached 1.569 billion yuan, reflecting a year-on-year increase of 5.55% [1] - Revenue growth of 12.13% and net profit growth of 1.45% indicate stable financial performance despite market challenges [1] Innovation and R&D - The company prioritizes technological innovation and has established a strong mechanism for innovation through collaborations with universities and research institutions [1] - Haosen Pharmaceutical holds 25 authorized patents, with 23 being invention patents, covering key preparation processes and equipment [1] - The collaboration with Hangzhou Haosen Drug Research Institute has enhanced R&D efficiency and market responsiveness [1] Market Expansion - The company is actively expanding into high-end markets in the Americas and Europe, enhancing brand influence through participation in international exhibitions [1] - Establishing long-term partnerships with leading global clients like TEVA has strengthened its position in the global pharmaceutical supply chain [1] Industry Outlook - Haosen Pharmaceutical anticipates continued growth in the emerging pharmaceutical sector, viewing the bulk procurement of chemical drugs as an opportunity for raw material pharmaceutical companies [1]

Core Insights - The company reported a revenue of 116,781,310.01 yuan for the third quarter of 2025, representing a year-on-year increase of 6.74% [2] - The net profit attributable to shareholders of the listed company was 27,415,463.98 yuan, showing a year-on-year decrease of 5.17% [2] Financial Performance - Revenue for Q3 2025: 116.78 million yuan, up 6.74% year-on-year [2] - Net profit for Q3 2025: 27.42 million yuan, down 5.17% year-on-year [2]

Core Insights - The company reported a revenue of 359 million yuan for the first three quarters of 2025, reflecting a year-on-year growth of 12.13% [1] - The net profit attributable to shareholders for the same period was approximately 88.21 million yuan, showing a year-on-year increase of 1.45% [1] - In the third quarter, the company achieved a revenue of 117 million yuan, which is a year-on-year increase of 6.74% [1] - The net profit for the third quarter was approximately 27.42 million yuan, indicating a year-on-year decline of 5.17% [1]

Core Viewpoint - Haosen Pharmaceutical (001367.SZ) reported a year-on-year increase in revenue and net profit for the first three quarters of the year, indicating stable growth despite a slight decline in net profit after excluding non-recurring items [1] Financial Performance - The company's operating revenue for the first three quarters reached 359 million yuan, representing a year-on-year growth of 12.13% [1] - The net profit attributable to shareholders of the listed company was approximately 88.21 million yuan, showing a year-on-year increase of 1.45% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was about 84.76 million yuan, reflecting a year-on-year decline of 1.56% [1]